Effects of α1 and β‐adrenergic antagonists and 5‐hydroxytryptamine receptor antagonist on portal‐systemic collateral vascular resistance in conscious rats with portal hypertension
- 1 October 1992
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 7 (5) , 449-454
- https://doi.org/10.1111/j.1440-1746.1992.tb01018.x
Abstract
In order to study the acute effects of pharmacological agents on the vascular resistance of portal-systemic collaterals, a model of total portal vein occlusion with 100% portal-systemic shunts was developed in the conscious rat. The haemodynamic effects of several vaso-active substances were evaluated in this model and compared with those obtained after saline administration. Prazosin (0.5 mg), an alpha 1-adrenergic antagonist, significantly reduced mean arterial pressure by 29%, portal pressure from 13.8 +/- 1.0(mean +/- s.e.m.) to 10.1 +/- 0.4 mmHg and portal tributary blood flow (radioactive microspheres) from 13.6 +/- 2.1 to 11.7 +/- 1.2 mL/min. It also decreased portal-systemic vascular resistance from 95 +/- 16 to 73 +/- 9 dyn s/cm5 x 10(3). Propranolol (4 mg), a beta-adrenergic antagonist, significantly reduced mean arterial pressure by 12% and portal pressure from 15.5 +/- 1.2 to 13.3 +/- 0.9 mmHg while reducing portal tributary blood flow from 14.6 +/- 1.5 to 11.0 +/- 1.7 mL/min and increasing portal systemic collateral vascular resistance from 88 +/- 7 to 103 +/- 8 dyn s/cm5 x 10(3). Ketanserin (0.25 mg/kg), a 5-hydroxytryptamine receptor antagonist, reduced portal pressure from 15.8 +/- 1.0 to 13.3 +/- 0.7 mmHg at a dose that did not alter mean arterial pressure or portal tributary blood flow. It achieved this by reducing portal-systemic collateral vascular resistance from 90 +/- 14 to 74 +/- 13 dyn s/cm5 x 10(3). Saline had no significant effect on systemic and splanchnic haemodynamics. This study shows that ketanserin decreases vascular resistance of portal-systemic collaterals while propranolol increases it. Thus, it is suggested that collateral vascular resistance is accessible to pharmacological manipulation.Keywords
This publication has 29 references indexed in Scilit:
- Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patientsHepatology, 1989
- Model for the study of portal-systemic collateral vascular resistance in the conscious ratJournal of Pharmacological Methods, 1988
- Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive ratsHepatology, 1988
- Drugs for portal hypertensionJournal of Gastroenterology and Hepatology, 1987
- Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: Possible role of serotonergic mechanisms in portal hypertensionHepatology, 1987
- Increased Portal Venous Resistance Hinders Portal Pressure Reduction During the Administration of β–Adrenergic Blocking Agents in A Portal Hypertensive ModelHepatology, 1985
- Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosisJournal of Hepatology, 1985
- Serotonergic Mechanisms in Isolated Human Peripheral Arteries and VeinsJournal of Cardiovascular Pharmacology, 1985
- Postsynaptic α-Adrenoceptor Subtypes in Rabbit Blood Vessels and Rat Anococcygeus Muscle Studied In VitroJournal of Cardiovascular Pharmacology, 1981
- Prehepatic Portal Hypertension in the RatEuropean Surgical Research, 1979